Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EBITDA (2016 - 2025)

Prestige Consumer Healthcare has reported EBITDA over the past 16 years, most recently at $48.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 1.39% year-over-year to $48.1 million; the TTM value through Dec 2025 reached $196.4 million, down 2.9%, while the annual FY2025 figure was $211.4 million, 2.44% up from the prior year.
  • EBITDA for Q4 2025 was $48.1 million at Prestige Consumer Healthcare, up from $42.9 million in the prior quarter.
  • Over five years, EBITDA peaked at $60.5 million in Q4 2023 and troughed at -$242.6 million in Q1 2023.
  • A 5-year average of $35.3 million and a median of $50.6 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 531.25% in 2023 and later skyrocketed 117.93% in 2024.
  • Year by year, EBITDA stood at $51.4 million in 2021, then increased by 14.57% to $58.9 million in 2022, then grew by 2.7% to $60.5 million in 2023, then decreased by 21.66% to $47.4 million in 2024, then increased by 1.39% to $48.1 million in 2025.
  • Business Quant data shows EBITDA for PBH at $48.1 million in Q4 2025, $42.9 million in Q3 2025, and $52.9 million in Q2 2025.